Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Johnson and Johnson
Colorcon
Moodys
Chinese Patent Office
Covington
Merck
Dow
Citi
US Army

Generated: May 24, 2018

DrugPatentWatch Database Preview

Details for Patent: 7,759,394

« Back to Dashboard

Which drugs does patent 7,759,394 protect, and when does it expire?

Patent 7,759,394 protects CAMBIA and is included in one NDA.

This patent has twenty-six patent family members in twenty-one countries.
Summary for Patent: 7,759,394
Title:Diclofenac formulations and methods of use
Abstract:Methods and formulations are provided for treating migraine and other acute pain episodes using diclofenac, and formulations of diclofenac that provide both rapid and sustained relief from acute pain. Methods and formulations are also provided for treating symptoms that often accompany migraine and acute pain such as photophobia, phonophobia, nausea and vomiting.
Inventor(s): Reiner; Giorgio (Como, IT), Reiner; Alberto (Como, IT), Meyer; Andreas (Neuenburg, DE)
Assignee: APR Applied Pharma Research SA (Balerna, CH)
Application Number:11/455,120
Patent Litigation and PTAB cases: See patent lawsuits and PTAB cases for patent 7,759,394
Patent Claim Types:
see list of patent claims
Use; Formulation;

Drugs Protected by US Patent 7,759,394

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted
Depomed Inc CAMBIA diclofenac potassium FOR SOLUTION;ORAL 022165-001 Jun 17, 2009 AB RX Yes Yes ➤ Sign Up ➤ Sign Up Y Y ACUTE TREATMENT OF MIGRAINE ATTACKS WITH OR WITHOUT AURA IN ADULTS ➤ Sign Up
Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Patent Submitted

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

Non-Orange Book US Patents Family Members for Patent 7,759,394

For Orange Book-listed patents (shown in the main table above) generic applications must certify that the listed patents are expired, invalid, or will not be infringed by generic entry.

The non-Orange Book patents listed below do not require formal certifications, so they do not automatically impede generic entry. Instead, they represent potential opportunities for branded firms to block generic entry through patent infringment challenges.

Patent No. Title Estimated Patent Expiration
9,827,197 Diclofenac formulations and methods of use ➤ Sign Up
8,097,651 Diclofenac formulations and methods of use ➤ Sign Up
8,927,604 Diclofenac formulations and methods of use ➤ Sign Up
Patent No. Title Estimated Patent Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

International Family Members for US Patent 7,759,394

Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
European Patent Office 2705837 ➤ Sign Up
European Patent Office 2402003 ➤ Sign Up
European Patent Office 3103441 ➤ Sign Up
Spain 2641889 ➤ Sign Up
Country Document Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration

This preview shows a limited data set. Subscribe for full access, or try a Free Trial

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Citi
Johnson and Johnson
Cerilliant
McKesson
Boehringer Ingelheim
Deloitte
UBS
Medtronic
Baxter

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.